MBX-102/JNJ39659100, a Novel Non-TZD Selective Partial PPAR-𝛾 Agonist Lowers Triglyceride Independently of PPAR-𝛼 Activation

Figure 3

Effect of MBX-102 (100 mg/kg) and rosiglitazone (4 mg/kg) on fasting plasma glucose (a), triglycerides (b), FFA (c), and cholesterol (d) levels during the course of treatment of male ZDF rats. Values are plotted as mean  ±  SEM (∗: 𝑃<.05, ∗∗: 𝑃<.01, ∗∗∗: 𝑃<.001 versus ZDF vehicle; #: 𝑃<.05, ##: 𝑃<.01, ###: 𝑃<.001 versus MBX-102-treated group, 2-way ANOVA followed by Bonferroni post tests). (e) Fasting plasma glucose, insulin, triglycerides, and FFA levels on day 11. Values are plotted as mean percentage of vehicle  ±  SEM (NS: 𝑃>.05, ∗: 𝑃<.05, ∗∗: 𝑃<.01, ∗∗∗: 𝑃<.001 versus ZDF vehicle, ##: 𝑃<.01 versus MBX-102-treated group, 1-way ANOVA and Tukey's multiple comparison test).

(a)

(b)

(c)

(d)

(e)